Clal Biotechnology Industries

Clal Biotechnology Industries is owned by AAR Consortium. AAR Consortium has a direct presence in 14 countries.

AAR Consortium has 46 subsidiaries including A1, ABH Holdings and Access Industries.

They are in:

• Music30%
• Holding11%
• Other60%

View the org chart displaying its 12 main executives

Most searched biographies at Clal Biotechnology Industries

• Assaf Segal, Acting Chief Executive Officer
• Sigalia Heifetz, Director
• Yuval Yanai, Director

Create your alert
to follow the executive moves at Clal Biotechnology Industries.

AAR Consortium has 2,273 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
• Nuvation Bio has announced the acquisition of AnHeart  (posted on April 12 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Clal Biotechnology Industries

• MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
• MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
• Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
• BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
• BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
• Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
• Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study | European Psychiatry | Cambridge Core
• View more press releases Close

Social media about Clal Biotechnology Industries

• Clal Biotechnology Industries on Wikipedia, Google News & Yahoo Finance
• Clal Biotechnology Industries on LinkedIn, Twitter & YouTube

Contact by email its executives including Avi Fischer

Call Clal Biotechnology Industries at +972 ...

View the org chart

Register to receive your alert

Report an error